VTDigger54%
Cutting GLP-1 coverage may cost UVM Health more than it saves 36%
By Adrienne Gil53%
7/15/2026, 7:06:53 PM
BS Summary: This article contains 28 faulty reasoning types, including False Dilemma, Indoctrination, and Biased Writer Voice, with Anecdotal as the most egregious example at 19.4% saturation with 143 hits. Analysis detected 1,303 faulty-reasoning hits from 737 analyzed words, generating a BS Score of 42.9% and a BS Rank of 36% (10,347 of 16,008 articles). This article is better (less manipulative) than 64.60% of the article peer group.
This commentary is by Adrienne Gil, who lives in Montpelier.
I understand that UVM Health is facing a serious financial crisis .
I understand that leaders are looking for savings and that eliminating coverage of GLP-1 medications for weight management under its employee health plan is expected to save the health network approximately $19 million a year.
But as someone whose health — and use of the healthcare system — has been fundamentally changed by this treatment, I believe this decision is shortsighted.
I have an autoimmune disease and developed fatty liver disease.
For years, I saw multiple doctors and specialists, including rheumatology; ear, nose and throat; primary care; and pulmonology.
I had repeated appointments, laboratory testing and ongoing medical care.
I was also doing what patients are told to do.
I worked with a nutritionist.
I exercised.
I changed my lifestyle.
I tried to lose weight.
As I entered menopause — a time when many women experience significant hormonal and metabolic changes — the weight still would not come off.
Then I started a GLP-1 medication.
I lost 50 pounds.
But this story is not really about 50 pounds.
My liver has returned to normal.
My markers of inflammation have returned to normal.
I am no longer seeing the long list of specialists I once needed.
My health has dramatically improved, and my use of expensive medical services has dramatically decreased.
So I have a question for UVM Health: When you calculated the projected $19 million in savings, did you factor in patients like me?
Did you calculate the specialist appointments I no longer need?
The laboratory testing and other medical care I no longer require?
The potential future costs of fatty liver disease, cardiovascular disease, diabetes, sleep apnea and other chronic conditions associated with obesity?
Or did you simply calculate the cost of the medication?
That distinction matters.
GLP-1 medications are expensive.
Health systems and employers have legitimate concerns about the rapidly rising costs.
I am not arguing that everyone should receive these medications without clinical criteria or cost controls.
But the answer to a difficult financial problem should not be a blanket exclusion that bars successful treatment for patients demonstrating measurable health improvements.
There are other options.
UVM Health could require prior authorization or stronger medical-necessity criteria.
It could continue coverage for patients who demonstrate meaningful clinical improvement.
It could require participation in nutrition and lifestyle programs.
It could prioritize patients at high risk for obesity-related disease.
It could protect current patients while developing more sustainable, evidence-based coverage criteria.
Instead, patients who have done everything asked of them — and who can demonstrate that the treatment is working — are being told their medication will simply no longer be covered.
There is a painful contradiction here.
UVM Health is a health care system.
It treats the consequences of obesity, cardiovascular disease, liver disease and other chronic conditions every day.
Yet it is withdrawing coverage of a treatment that, for some patients, has dramatically improved those very conditions.
My improvement is not a hypothetical future benefit.
It has already happened.
I am healthier today.
My liver is healthier.
My inflammation markers are normal.
I need fewer specialists.
I use fewer health care resources.
If UVM Health believes ending this coverage is the right decision, it should publicly release the full analysis behind it.
Patients and employees deserve to know whether the projected savings account only for the cost of these medications, or whether the analysis also considered health outcomes and reduced medical utilization among patients whose conditions have significantly improved.
They also deserve to know why UVM Health chose a blanket exclusion rather than a targeted approach that preserves coverage for patients demonstrating meaningful clinical benefit.
I am asking UVM Health to reconsider this decision before it takes effect in September.
At a minimum, the network should protect continuity of care for current patients while it develops evidence-based continuation criteria and explores more sustainable alternatives.
UVM Health is facing a real financial crisis.
But a financial crisis should not lead a health care system to make decisions based only on what a patient costs today without asking what keeping that patient healthy could prevent tomorrow.
My story is one example.
I suspect there are many more.
Read the story on VTDigger here: Cutting GLP-1 coverage may cost UVM Health more than it saves .
Analysis
Hover over highlighted words in the article to view the associated bias or fallacy analysis.